ITM, which holds a U.S. drug master file with the Food and Drug Administration for n.c.a. Lu-177 and has marketing authorization in the European Union (brand name EndolucinBeta), has exclusive access to IPS’s irradiation services for the production of Lu-177. The company will use the increased supply of radioisotopes from the system to meet a growing medical demand.

Bruce Power will collaborate with Ontario’s Saugeen Ojibway Nation to market the new isotope supply in an equity partnership named Gamzook’aamin Aakoziwin (Fighting Cancer Together).

In announcing the commencement of production on October 24, David Harris, chief executive officer of Kinectrics, said, “Today we celebrate the efforts of Bruce Power, ITM, our Kinectrics staff, and our partner in Isogen, Framatome, whose collective efforts enabled the start of commercial supply of lutetium-177. This day marks a paradigm shift in medical isotope supply wherein the international medical community can now depend on scalable, reliable, Canadian power reactor–produced isotopes for their cancer treatments.”

Research & Applications continues

For over fifty years, Presray’s innovative doors, windows and barriers have been used to protect vital buildings and facilities across America. With our experience, and broad product offering, we can help you meet the evolving needs of the nuclear industry.